8-K: Traws Pharma Announces $50 Million At-The-Market Offering

Traws Pharma, Inc. has entered into an At The Market Offering Agreement with Citizens JMP Securities, LLC to sell up to $50 million of its common stock.

Summary

• Traws Pharma, Inc. has entered into an At The Market Offering Agreement (ATM Agreement) with Citizens JMP Securities, LLC, dated March 10, 2025.
• Under the ATM Agreement, Traws Pharma may offer and sell shares of its common stock with an aggregate sales price of up to $50 million.
• Sales will be made through Citizens JMP Securities, acting as sales agent and/or principal, via methods defined as 'at the market offering' under Rule 415(a)(4) of the Securities Act of 1933.
• These methods include sales on the Nasdaq Capital Market, directly to Citizens as principal, in privately negotiated transactions, or in block transactions.
• Citizens will use commercially reasonable efforts to sell shares based on Traws Pharma's instructions, including any price, time, or size limits.
• Traws Pharma is not obligated to make any sales under the ATM Agreement, and there is no assurance that any shares will be sold.
• The ATM Agreement can be terminated by Traws Pharma with five business days' notice, by Citizens at their discretion, or as otherwise permitted in the agreement.
• The shares will be sold under an effective shelf registration statement on Form S-3, filed on June 30, 2023, and declared effective on July 11, 2023, as supplemented by a prospectus supplement dated March 10, 2025.
• Under the prospectus supplement, Traws Pharma may offer and sell shares with an aggregate offering price of up to $5,514,200, which is the company's current 'baby shelf' limitation under General Instruction I.B.6 of Form S-3.
• Traws Pharma will pay Citizens a commission at a fixed rate of 3.0% of the gross proceeds from each sale.
• Traws Pharma will also reimburse Citizens for legal counsel fees up to $50,000 in the aggregate, plus up to $5,000 per Representation Date for ongoing diligence.
• Traws Pharma has made customary representations, warranties, and covenants in the ATM Agreement, and has provided Citizens with customary indemnification rights.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the ATM offering provides a means for raising capital, it also introduces potential dilution and market risks. The company's ability to successfully execute the offering and utilize the proceeds effectively will determine the ultimate impact.

Positives

• The ATM offering provides Traws Pharma with flexibility in raising capital.
• The company has access to an existing shelf registration statement, streamlining the offering process.
• The agreement allows for various methods of selling shares, potentially optimizing execution.
• The company retains the right to terminate the agreement with five business days' notice.

Negatives

• There is no guarantee that Traws Pharma will sell any shares under the ATM Agreement.
• The company will incur commission expenses of 3.0% on any shares sold.
• The offering could dilute existing shareholders' equity.
• The company may offer and sell shares with an aggregate offering price of up to $5,514,200, which is the company's current 'baby shelf' limitation under General Instruction I.B.6 of Form S-3.

Risks

• Market conditions may not be favorable for selling shares at desired prices.
• The offering could put downward pressure on the company's stock price.
• The company's reliance on Citizens to sell shares exposes it to execution risk.
• The company may not be able to raise the full $50 million contemplated by the agreement.

Future Outlook

The company may offer and sell shares of its common stock from time to time, but there is no guarantee that any shares will be sold or the amount of proceeds that will be raised.

Industry Context

At-the-market offerings are a common method for publicly traded companies, particularly in the biotech and pharmaceutical sectors, to raise capital opportunistically. This allows companies to take advantage of favorable market conditions or specific company developments to issue shares without the need for a traditional underwritten offering.

Comparison to Industry Standards

• The 3.0% commission rate is within the typical range for ATM offerings, which can vary based on the size of the offering and the complexity of the sales process.
• Comparable companies such as XOMA Corporation and Agenus Inc. have utilized ATM offerings with similar commission structures.
• The 'baby shelf' limitation of $5,514,200 is a common constraint for smaller companies using Form S-3, reflecting regulatory restrictions on the amount of securities that can be offered within a 12-month period.

Stakeholder Impact

• Shareholders may experience dilution if the company sells a significant number of shares.
• The company's financial position could be strengthened if the offering is successful.
• The offering could provide the company with additional capital to fund its operations and growth initiatives.

Next Steps

• Traws Pharma may, from time to time, issue Sales Notices to Citizens JMP Securities instructing them to sell shares.
• Citizens JMP Securities will use commercially reasonable efforts to sell the shares based on the company's instructions.
• The company will file required reports with the SEC regarding the sales of shares under the ATM Agreement.

Key Dates